Skip to main content
Erschienen in: Current Cardiovascular Risk Reports 6/2010

01.11.2010

Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease

verfasst von: Ian J. Brown, Paul Elliott

Erschienen in: Current Cardiovascular Risk Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Judgments as to causality of associations between risk factors and disease involve a weighing of the available evidence from animal and human studies. The human data include observational studies, results of which may be confounded, and randomized trials, which may be unavailable or infeasible, thus limiting the ability to make causal inference. Mendelian randomization offers an additional approach to help assess causality. The concept relies on the random assignment of alleles at meiosis as the basis for a natural randomized experiment linking genetic variants to intermediate risk factors and disease. Recent Mendelian randomization studies have provided evidence for a causal role of serum lipoprotein(a) in coronary heart disease, and against a causal role for plasma C-reactive protein. Although a valid Mendelian randomization experiment is subject to a number of assumptions and limitations, it is a useful adjunct to assess causality, especially when randomized trials are unavailable.
Literatur
1.
Zurück zum Zitat Davey Smith G, Ebrahim S: ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003, 32:1–22.PubMedCrossRef Davey Smith G, Ebrahim S: ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003, 32:1–22.PubMedCrossRef
2.
Zurück zum Zitat •• Sheehan NA, Didelez V, Burton PR, Tobin MD: Mendelian randomisation and causal inference in observational epidemiology. PLoS Medicine 2008, 5:e177. This article describes the Mendelian randomization concept, summarizes key assumptions and limitations, and provides several examples to illustrate how Mendelian randomization is used in practice.PubMedCrossRef •• Sheehan NA, Didelez V, Burton PR, Tobin MD: Mendelian randomisation and causal inference in observational epidemiology. PLoS Medicine 2008, 5:e177. This article describes the Mendelian randomization concept, summarizes key assumptions and limitations, and provides several examples to illustrate how Mendelian randomization is used in practice.PubMedCrossRef
3.
Zurück zum Zitat Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 2008, 299:1335–1344.PubMedCrossRef Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 2008, 299:1335–1344.PubMedCrossRef
4.
Zurück zum Zitat Greenland S: An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000, 29:722–729.PubMedCrossRef Greenland S: An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000, 29:722–729.PubMedCrossRef
5.
Zurück zum Zitat Katan MB: Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986, i:507–508.CrossRef Katan MB: Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986, i:507–508.CrossRef
6.
Zurück zum Zitat Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202–1206.PubMedCrossRef Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202–1206.PubMedCrossRef
7.
Zurück zum Zitat Klerk M, Verhoef P, Clarke R, et al.: MTHFR 677C-->T polymorphism and risk of coronary heart disease. A meta-analysis. JAMA 2002, 288:2023–2031. Klerk M, Verhoef P, Clarke R, et al.: MTHFR 677C-->T polymorphism and risk of coronary heart disease. A meta-analysis. JAMA 2002, 288:2023–2031.
8.
Zurück zum Zitat Lewis SJ, Ebrahim S, Davey Smith G: Meta-analysis of MTHFR 677C-->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005, 331:1053–1056.PubMedCrossRef Lewis SJ, Ebrahim S, Davey Smith G: Meta-analysis of MTHFR 677C-->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005, 331:1053–1056.PubMedCrossRef
9.
Zurück zum Zitat Den Heijer M, Lewington S, Clarke R: Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005, 3:292–299.CrossRef Den Heijer M, Lewington S, Clarke R: Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005, 3:292–299.CrossRef
10.
Zurück zum Zitat Cronin S, Furie KL, Kelly PJ: Dose-related association of MTHFR 677T allele with risk of ischemic stroke. Evidence from a cumulative meta-analysis. Stroke 2005, 36:1581–1587.PubMedCrossRef Cronin S, Furie KL, Kelly PJ: Dose-related association of MTHFR 677T allele with risk of ischemic stroke. Evidence from a cumulative meta-analysis. Stroke 2005, 36:1581–1587.PubMedCrossRef
11.
Zurück zum Zitat Casas JP, Bautista LE, Smeeth L, et al.: Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005, 365:224–232.PubMed Casas JP, Bautista LE, Smeeth L, et al.: Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005, 365:224–232.PubMed
12.
Zurück zum Zitat Davey Smith G, Harbord R, Milton J, et al.: Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005, 25:2228–2233. Davey Smith G, Harbord R, Milton J, et al.: Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005, 25:2228–2233.
13.
Zurück zum Zitat Keavney B, Danesh J, Parish S, et al.: Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int J Epidemiol 2006, 35:935–943.PubMedCrossRef Keavney B, Danesh J, Parish S, et al.: Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int J Epidemiol 2006, 35:935–943.PubMedCrossRef
14.
Zurück zum Zitat Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264–1272.PubMedCrossRef Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264–1272.PubMedCrossRef
15.
Zurück zum Zitat • Kathiresan S, Melander O, Anevski D, et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. NEJM 2008, 358:1240–1249. This article reports significant associations among SNPs at nine loci, LDL and HDL cholesterol, and incident CVD.PubMedCrossRef • Kathiresan S, Melander O, Anevski D, et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. NEJM 2008, 358:1240–1249. This article reports significant associations among SNPs at nine loci, LDL and HDL cholesterol, and incident CVD.PubMedCrossRef
16.
Zurück zum Zitat Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al.: Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524–2532.PubMedCrossRef Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al.: Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524–2532.PubMedCrossRef
17.
Zurück zum Zitat • Aulchenko YS, Ripatti S, Lindqvist I, et al.: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009, 41:47–55. In a genome-wide analysis of 16 European cohorts and up to 22,562 participants, significant associations were observed among SNPs in 16 loci, multiple serum lipid parameters, carotid IMT, and CHD incidence.PubMedCrossRef • Aulchenko YS, Ripatti S, Lindqvist I, et al.: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009, 41:47–55. In a genome-wide analysis of 16 European cohorts and up to 22,562 participants, significant associations were observed among SNPs in 16 loci, multiple serum lipid parameters, carotid IMT, and CHD incidence.PubMedCrossRef
18.
Zurück zum Zitat Timpson NJ, Harbord R, Davey Smith G, et al.: Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009, 54:84–90. Timpson NJ, Harbord R, Davey Smith G, et al.: Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009, 54:84–90.
19.
Zurück zum Zitat Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423–1427.PubMedCrossRef Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423–1427.PubMedCrossRef
20.
Zurück zum Zitat Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction on blood pressure. A meta-analysis of randomized control trials. Hypertension 2003, 42:878–884.PubMedCrossRef Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction on blood pressure. A meta-analysis of randomized control trials. Hypertension 2003, 42:878–884.PubMedCrossRef
21.
Zurück zum Zitat • Emerging Risk Factors Collaboration: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993–2000. This pooled analysis of more than 300,000 individuals from 68 prospective cohorts confirmed associations of serum lipids and apolipoproteins with incident CHD. The authors concluded that lipid assessment in vascular disease could be simplified to measurement of nonfasting total and HDL cholesterol levels, or apolipoproteins. • Emerging Risk Factors Collaboration: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993–2000. This pooled analysis of more than 300,000 individuals from 68 prospective cohorts confirmed associations of serum lipids and apolipoproteins with incident CHD. The authors concluded that lipid assessment in vascular disease could be simplified to measurement of nonfasting total and HDL cholesterol levels, or apolipoproteins.
22.
Zurück zum Zitat Preiss D, Sattar N: Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009, 70:815–828.CrossRef Preiss D, Sattar N: Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009, 70:815–828.CrossRef
23.
Zurück zum Zitat • Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634–1639. In a pooled analysis of more than 25,000 cases and 35,000 controls, a SNP in the APOA5 gene was associated with serum triglyceride levels and CHD risk, but interpretation is complicated by the association of the SNP with HDL levels (pleiotropy). • Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634–1639. In a pooled analysis of more than 25,000 cases and 35,000 controls, a SNP in the APOA5 gene was associated with serum triglyceride levels and CHD risk, but interpretation is complicated by the association of the SNP with HDL levels (pleiotropy).
24.
Zurück zum Zitat Kamstrup PR: Lipoprotein(a) and ischemic heart disease—a causal association? A review. Atherosclerosis 2010, 211:15–23.PubMedCrossRef Kamstrup PR: Lipoprotein(a) and ischemic heart disease—a causal association? A review. Atherosclerosis 2010, 211:15–23.PubMedCrossRef
25.
Zurück zum Zitat Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082–1085.PubMed Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082–1085.PubMed
26.
Zurück zum Zitat • Emerging Risk Factors Collaboration: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412–423. In a pooled analysis of more than 125,000 individuals from 36 studies, elevated lipoprotein(a) levels were associated with increased risk of CHD and stroke. • Emerging Risk Factors Collaboration: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412–423. In a pooled analysis of more than 125,000 individuals from 36 studies, elevated lipoprotein(a) levels were associated with increased risk of CHD and stroke.
27.
Zurück zum Zitat •• Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331–2339. Genetic variants were associated with lipoprotein(a) levels and myocardial infarction risk in case-control and prospective Copenhagen cohorts. The magnitude of the genetic variant-CHD effect was consistent with observational findings for lipoprotein(a) levels.PubMedCrossRef •• Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331–2339. Genetic variants were associated with lipoprotein(a) levels and myocardial infarction risk in case-control and prospective Copenhagen cohorts. The magnitude of the genetic variant-CHD effect was consistent with observational findings for lipoprotein(a) levels.PubMedCrossRef
28.
Zurück zum Zitat •• Clarke R, Peden JF, Hopewell JC, et al.: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518–2528. Genetic variants were associated with lipoprotein(a) levels and CHD risk in a pooled analysis of 4 case-control studies. PubMedCrossRef •• Clarke R, Peden JF, Hopewell JC, et al.: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518–2528. Genetic variants were associated with lipoprotein(a) levels and CHD risk in a pooled analysis of 4 case-control studies. PubMedCrossRef
29.
Zurück zum Zitat Rifai N, Ma J, Sacks FM, et al.: Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem 2004, 50:1364–1371.PubMedCrossRef Rifai N, Ma J, Sacks FM, et al.: Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem 2004, 50:1364–1371.PubMedCrossRef
30.
Zurück zum Zitat Paultre F, Pearson TA, Weil HF, et al.: High levels of Lp(a) with a small Apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000, 20:2619–2624.PubMed Paultre F, Pearson TA, Weil HF, et al.: High levels of Lp(a) with a small Apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000, 20:2619–2624.PubMed
31.
Zurück zum Zitat Verma S, Szmitko PE, Ridker PM: C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005, 2:29–36.PubMedCrossRef Verma S, Szmitko PE, Ridker PM: C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005, 2:29–36.PubMedCrossRef
32.
Zurück zum Zitat Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387–1397.PubMedCrossRef Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387–1397.PubMedCrossRef
33.
Zurück zum Zitat Shah T, Casas JP, Cooper JA, et al.: Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38:217–231.PubMedCrossRef Shah T, Casas JP, Cooper JA, et al.: Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38:217–231.PubMedCrossRef
34.
Zurück zum Zitat Casas JP, Shah T, Cooper J, et al.: Insight into the nature of the CRP-coronary even association using Mendelian randomization. Int J Epidemiol 2006, 35:922–931.PubMedCrossRef Casas JP, Shah T, Cooper J, et al.: Insight into the nature of the CRP-coronary even association using Mendelian randomization. Int J Epidemiol 2006, 35:922–931.PubMedCrossRef
35.
Zurück zum Zitat Kardys I, de Maat MP, Uitterlinden AG, et al.: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J 2006, 27:1331–1337.PubMedCrossRef Kardys I, de Maat MP, Uitterlinden AG, et al.: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J 2006, 27:1331–1337.PubMedCrossRef
36.
Zurück zum Zitat Lawlor DA, Harbord RM, Timpson NJ, et al.: The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008, 3:e3011.PubMedCrossRef Lawlor DA, Harbord RM, Timpson NJ, et al.: The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS One 2008, 3:e3011.PubMedCrossRef
37.
Zurück zum Zitat • Zacho J, Tybjærg-Hansen A, Skov Jensen J, et al.: Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359:1897–1908. Genetic variants were associated with CRP levels, but not CHD or stroke, in a pooled analysis of cross-sectional, case-control and prospective Copenhagen cohorts.PubMedCrossRef • Zacho J, Tybjærg-Hansen A, Skov Jensen J, et al.: Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359:1897–1908. Genetic variants were associated with CRP levels, but not CHD or stroke, in a pooled analysis of cross-sectional, case-control and prospective Copenhagen cohorts.PubMedCrossRef
38.
Zurück zum Zitat •• Elliott P, Chambers JC, Zhang W, et al.: Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37–48. Genetic variants were associated with CRP levels, but not CHD risk, in pooled analysis of 25 case-control and prospective studies involving more than 28,000 cases and 100,000 controls. This article provides the most compelling evidence to date that raised CRP levels are a consequence, rather than a cause, of CHD.PubMedCrossRef •• Elliott P, Chambers JC, Zhang W, et al.: Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37–48. Genetic variants were associated with CRP levels, but not CHD risk, in pooled analysis of 25 case-control and prospective studies involving more than 28,000 cases and 100,000 controls. This article provides the most compelling evidence to date that raised CRP levels are a consequence, rather than a cause, of CHD.PubMedCrossRef
39.
Zurück zum Zitat Kivimäki M, Lawlor DA, Eklund C, et al.: Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the Young Finns Study. Arterioscler Thromb Vasc Biol 2007, 27:978–979.PubMedCrossRef Kivimäki M, Lawlor DA, Eklund C, et al.: Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the Young Finns Study. Arterioscler Thromb Vasc Biol 2007, 27:978–979.PubMedCrossRef
40.
Zurück zum Zitat Kivimäki M, Lawlor DA, Davey Smith G, et al.: Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One 2008, 3:e3013.PubMedCrossRef Kivimäki M, Lawlor DA, Davey Smith G, et al.: Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One 2008, 3:e3013.PubMedCrossRef
41.
Zurück zum Zitat • Casas JP, Ninio E, Panayiotou A, et al.: PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10494 cases and 15624 controls of European Ancestry. Circulation 2010, 121:2284–2293. Genetic variants were associated with small but significant differences in Lp-PLA 2 activity levels, but not CHD risk, in pooled analysis of 12 studies.PubMedCrossRef • Casas JP, Ninio E, Panayiotou A, et al.: PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10494 cases and 15624 controls of European Ancestry. Circulation 2010, 121:2284–2293. Genetic variants were associated with small but significant differences in Lp-PLA 2 activity levels, but not CHD risk, in pooled analysis of 12 studies.PubMedCrossRef
42.
Zurück zum Zitat • Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536–1544. In a pooled analysis of more than 79,000 individuals from 32 prospective studies, elevated Lp-PLA 2 activity and mass were associated with increased risk of CHD, stroke, total vascular disease, and nonvascular disease. • Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536–1544. In a pooled analysis of more than 79,000 individuals from 32 prospective studies, elevated Lp-PLA 2 activity and mass were associated with increased risk of CHD, stroke, total vascular disease, and nonvascular disease.
43.
Zurück zum Zitat Hou L, Chen S, Yu H, et al.: Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009, 125:11–20.PubMedCrossRef Hou L, Chen S, Yu H, et al.: Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009, 125:11–20.PubMedCrossRef
44.
Zurück zum Zitat Enomoto N, Takase S, Yasuhara M, Takada A: Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res 1991, 15:141–144.PubMedCrossRef Enomoto N, Takase S, Yasuhara M, Takada A: Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res 1991, 15:141–144.PubMedCrossRef
45.
Zurück zum Zitat • Chen L, Davey Smith G, Harbord RM, Lewis SJ: Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Medicine 2008, 5:e52. A genetic variant in the ALDH2 gene was associated with reduced alcohol consumption, reduced blood pressure, and reduced risk of prevalent hypertension in a pooled analysis of eight studies of Japanese men. This article demonstrates how the Mendelian randomization concept can be used to assess the causality of behavioral exposures, rather than intermediate phenotypes.PubMedCrossRef • Chen L, Davey Smith G, Harbord RM, Lewis SJ: Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Medicine 2008, 5:e52. A genetic variant in the ALDH2 gene was associated with reduced alcohol consumption, reduced blood pressure, and reduced risk of prevalent hypertension in a pooled analysis of eight studies of Japanese men. This article demonstrates how the Mendelian randomization concept can be used to assess the causality of behavioral exposures, rather than intermediate phenotypes.PubMedCrossRef
46.
Zurück zum Zitat Marmot MG, Elliott P, Shipley MJ, et al.: Alcohol and blood pressure: the INTERSALT Study. BMJ 1994, 308:1263–1267.PubMed Marmot MG, Elliott P, Shipley MJ, et al.: Alcohol and blood pressure: the INTERSALT Study. BMJ 1994, 308:1263–1267.PubMed
47.
Zurück zum Zitat Fuchs FD, Chambless LE, Whelton PK, et al.: Alcohol consumption and the risk of incidence of hypertension: the Athersclerosis Risk in Communities Study. Hypertension 2001, 37:1242–1250.PubMed Fuchs FD, Chambless LE, Whelton PK, et al.: Alcohol consumption and the risk of incidence of hypertension: the Athersclerosis Risk in Communities Study. Hypertension 2001, 37:1242–1250.PubMed
48.
Zurück zum Zitat Thanassoulis G, O’Donnell CJ: Mendelian randomization: nature’s randomized trial in the post-genome era. JAMA 2009, 301:2386–2388.PubMedCrossRef Thanassoulis G, O’Donnell CJ: Mendelian randomization: nature’s randomized trial in the post-genome era. JAMA 2009, 301:2386–2388.PubMedCrossRef
Metadaten
Titel
Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease
verfasst von
Ian J. Brown
Paul Elliott
Publikationsdatum
01.11.2010
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Risk Reports / Ausgabe 6/2010
Print ISSN: 1932-9520
Elektronische ISSN: 1932-9563
DOI
https://doi.org/10.1007/s12170-010-0127-3

Weitere Artikel der Ausgabe 6/2010

Current Cardiovascular Risk Reports 6/2010 Zur Ausgabe

Clinical Trial Report

Assessment of the JUPITER Trial

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.